Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection

Aymin Delgado-Borrego, David Healey, Betania Negre, Marielle Christofi, Sabina Sabharwal, David Ludwig, Raymond T. Chung, Maureen M. Jonas

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background and Aims: Evidence demonstrates that obesity is associated with progression of chronic hepatitis C virus (HCV) infection and poor response to interferon therapy among HCV-infected adults. However, this evidence has been confounded by multiple comorbidities present in adult cohorts and the use of single adult doses. Patients and Methods: We performed a retrospective investigation to evaluate the role of body mass index (BMI) in chronic HCV progression and response to therapy in the children. One hundred twenty-three children and teenagers studied at Children's Hospital Boston for HCV infection between 1998 and 2007 were included. Patients' weight and height at the time of liver biopsy or before and after HCV therapy were obtained and BMI was calculated. Results: The presence of steatosis was statistically associated with higher mean (±SE) BMI percentiles (72nd ± 5.8 vs 58th ± 3.5) percentile; F(1,101) = 4.2, P = 0.04. Nonresponders to treatment had a higher mean (±SE) BMI percentile (70th ± 7.4) when compared with responders (50th ± 6.5) in univariate and multivariate analyses (P = 0.04, P = 0.02, respectively). Using a multivariate model, it was calculated that 1 standard deviation (1 z-score unit) increase in baseline BMI z score is associated with a 12% decrease in the probability of sustained virologic response. Conclusions: Overweight adversely affects the progression of chronic HCV liver disease and is associated with diminished response to antiviral therapy using weight-based dosing in a cohort with minimal comorbidities.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume51
Issue number2
DOIs
StatePublished - Aug 1 2010

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Body Mass Index
Pediatrics
Comorbidity
Therapeutics
Weights and Measures
Interferons
Antiviral Agents
Liver Diseases
Multivariate Analysis
Obesity
Biopsy
Liver

Keywords

  • fibrosis
  • interferon
  • obesity
  • pediatric
  • steatosis

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Delgado-Borrego, A., Healey, D., Negre, B., Christofi, M., Sabharwal, S., Ludwig, D., ... Jonas, M. M. (2010). Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. Journal of Pediatric Gastroenterology and Nutrition, 51(2), 191-197. https://doi.org/10.1097/MPG.0b013e3181d32756

Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. / Delgado-Borrego, Aymin; Healey, David; Negre, Betania; Christofi, Marielle; Sabharwal, Sabina; Ludwig, David; Chung, Raymond T.; Jonas, Maureen M.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 51, No. 2, 01.08.2010, p. 191-197.

Research output: Contribution to journalArticle

Delgado-Borrego, A, Healey, D, Negre, B, Christofi, M, Sabharwal, S, Ludwig, D, Chung, RT & Jonas, MM 2010, 'Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection', Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no. 2, pp. 191-197. https://doi.org/10.1097/MPG.0b013e3181d32756
Delgado-Borrego, Aymin ; Healey, David ; Negre, Betania ; Christofi, Marielle ; Sabharwal, Sabina ; Ludwig, David ; Chung, Raymond T. ; Jonas, Maureen M. / Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. In: Journal of Pediatric Gastroenterology and Nutrition. 2010 ; Vol. 51, No. 2. pp. 191-197.
@article{a31c6f5f451a4fd2bc3620c015ad1358,
title = "Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection",
abstract = "Background and Aims: Evidence demonstrates that obesity is associated with progression of chronic hepatitis C virus (HCV) infection and poor response to interferon therapy among HCV-infected adults. However, this evidence has been confounded by multiple comorbidities present in adult cohorts and the use of single adult doses. Patients and Methods: We performed a retrospective investigation to evaluate the role of body mass index (BMI) in chronic HCV progression and response to therapy in the children. One hundred twenty-three children and teenagers studied at Children's Hospital Boston for HCV infection between 1998 and 2007 were included. Patients' weight and height at the time of liver biopsy or before and after HCV therapy were obtained and BMI was calculated. Results: The presence of steatosis was statistically associated with higher mean (±SE) BMI percentiles (72nd ± 5.8 vs 58th ± 3.5) percentile; F(1,101) = 4.2, P = 0.04. Nonresponders to treatment had a higher mean (±SE) BMI percentile (70th ± 7.4) when compared with responders (50th ± 6.5) in univariate and multivariate analyses (P = 0.04, P = 0.02, respectively). Using a multivariate model, it was calculated that 1 standard deviation (1 z-score unit) increase in baseline BMI z score is associated with a 12{\%} decrease in the probability of sustained virologic response. Conclusions: Overweight adversely affects the progression of chronic HCV liver disease and is associated with diminished response to antiviral therapy using weight-based dosing in a cohort with minimal comorbidities.",
keywords = "fibrosis, interferon, obesity, pediatric, steatosis",
author = "Aymin Delgado-Borrego and David Healey and Betania Negre and Marielle Christofi and Sabina Sabharwal and David Ludwig and Chung, {Raymond T.} and Jonas, {Maureen M.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1097/MPG.0b013e3181d32756",
language = "English",
volume = "51",
pages = "191--197",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection

AU - Delgado-Borrego, Aymin

AU - Healey, David

AU - Negre, Betania

AU - Christofi, Marielle

AU - Sabharwal, Sabina

AU - Ludwig, David

AU - Chung, Raymond T.

AU - Jonas, Maureen M.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background and Aims: Evidence demonstrates that obesity is associated with progression of chronic hepatitis C virus (HCV) infection and poor response to interferon therapy among HCV-infected adults. However, this evidence has been confounded by multiple comorbidities present in adult cohorts and the use of single adult doses. Patients and Methods: We performed a retrospective investigation to evaluate the role of body mass index (BMI) in chronic HCV progression and response to therapy in the children. One hundred twenty-three children and teenagers studied at Children's Hospital Boston for HCV infection between 1998 and 2007 were included. Patients' weight and height at the time of liver biopsy or before and after HCV therapy were obtained and BMI was calculated. Results: The presence of steatosis was statistically associated with higher mean (±SE) BMI percentiles (72nd ± 5.8 vs 58th ± 3.5) percentile; F(1,101) = 4.2, P = 0.04. Nonresponders to treatment had a higher mean (±SE) BMI percentile (70th ± 7.4) when compared with responders (50th ± 6.5) in univariate and multivariate analyses (P = 0.04, P = 0.02, respectively). Using a multivariate model, it was calculated that 1 standard deviation (1 z-score unit) increase in baseline BMI z score is associated with a 12% decrease in the probability of sustained virologic response. Conclusions: Overweight adversely affects the progression of chronic HCV liver disease and is associated with diminished response to antiviral therapy using weight-based dosing in a cohort with minimal comorbidities.

AB - Background and Aims: Evidence demonstrates that obesity is associated with progression of chronic hepatitis C virus (HCV) infection and poor response to interferon therapy among HCV-infected adults. However, this evidence has been confounded by multiple comorbidities present in adult cohorts and the use of single adult doses. Patients and Methods: We performed a retrospective investigation to evaluate the role of body mass index (BMI) in chronic HCV progression and response to therapy in the children. One hundred twenty-three children and teenagers studied at Children's Hospital Boston for HCV infection between 1998 and 2007 were included. Patients' weight and height at the time of liver biopsy or before and after HCV therapy were obtained and BMI was calculated. Results: The presence of steatosis was statistically associated with higher mean (±SE) BMI percentiles (72nd ± 5.8 vs 58th ± 3.5) percentile; F(1,101) = 4.2, P = 0.04. Nonresponders to treatment had a higher mean (±SE) BMI percentile (70th ± 7.4) when compared with responders (50th ± 6.5) in univariate and multivariate analyses (P = 0.04, P = 0.02, respectively). Using a multivariate model, it was calculated that 1 standard deviation (1 z-score unit) increase in baseline BMI z score is associated with a 12% decrease in the probability of sustained virologic response. Conclusions: Overweight adversely affects the progression of chronic HCV liver disease and is associated with diminished response to antiviral therapy using weight-based dosing in a cohort with minimal comorbidities.

KW - fibrosis

KW - interferon

KW - obesity

KW - pediatric

KW - steatosis

UR - http://www.scopus.com/inward/record.url?scp=77955228622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955228622&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e3181d32756

DO - 10.1097/MPG.0b013e3181d32756

M3 - Article

C2 - 20531022

AN - SCOPUS:77955228622

VL - 51

SP - 191

EP - 197

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 2

ER -